30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Amedica

2013 revenue: $22.3MM, -3% (U.S. $22.2MM, +2%; ex-U.S. $0.1MM, -91%)

  • Silicon Nitride (SiNi) $7.6MM, +17%
  • Non-Silicon Nitride $14.6MM, -11%


  • Overall decrease attributed to one-time sale of non-SiNi products to ex-U.S. customer in 2012, sales/marketing restructure, timing of next-gen Valeo launch
  • SiNi growth supported primarily by launch of 2nd-gen interbody devices
  • In 2013, completed enrollment in prospective human clinical trial comparing porous SiNi vs. PEEK implants
  • In last 6 months, converted 40 new surgeons to SiNi products
  • In 4Q, entered into collaboration with Kyocera to co-manufacture SiNi devices, including spinal interbody, plus European distribution agreement with K2M
  • In 1Q14, commenced beta release of 2nd-gen TLIF device
  • Planning to launch 2nd-gen cervical implant by end of 3Q
  • Assuming FDA clearance, expects SiNi-coated total knee and total hip in 2H15